Dishman Pharma & Chem Peer Comparison

NSE: DISHMAN | BSE: 532526

₹301.20

₹7.95 (2.71%)

As on 29-May-2017IST

Market cap

₹4,859 Cr

Revenue (TTM)

₹1,672 Cr

P/E Ratio

30.1

P/B Ratio

Div. Yield

0.4 %

Edit

	Dishman Pharma & Chem	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	4,859	35,741	29,298	28,071	27,956
Revenue (₹ Cr)	1,672	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	162.05	414.00	288.22	-371.81	387.35
Net Margin (%)	9.50	11.23	14.79	-3.93	26.01
RoE (%)	4.97	8.38	29.77	-3.85	25.18
Price to Earnings	30.15	87.39	101.65	--	72.38
Price-To-Book	1.01	7.10	21.83	3.51	16.20

Income Statement (₹ Cr)

	Dishman Pharma & Chem	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	1,596.05	4,453.22	39.17	--	153.70
Total Income	1,622.59	4,519.32	39.64	--	156.57
Total Expenditure	1,185.73	3,958.98	29.32	--	135.51
EBITDA	410.32	494.24	9.85	--	18.19
Depreciation	109.06	141.91	4.71	--	0.80
EBIT	301.26	352.33	5.13	--	17.39
Interest	94.44	128.96	2.64	--	2.56
Other Income	26.54	66.10	0.47	--	2.87
Exceptional Items	--	--	--	--	--
Profit before Tax	233.36	289.47	2.96	--	17.70
Provision for Tax	62.36	37.88	2.05	--	5.04
Profit after Tax	171.00	251.59	0.92	--	12.66

	Dishman Pharma & Chem	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	1,451.55	3,775.12	48.41	--	27.42
Minority Interest	0.44	465.33	--	--	--
Non-Current Liabilities	576.84	1,893.49	12.24	--	15.21
Current Liabilities	951.70	1,841.85	31.04	--	48.60
Total Liabilities	2,980.53	8,073.64	91.69	--	92.39

	Dishman Pharma & Chem	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	1,878.74	4,023.94	56.39	--	24.90
Current Assets	1,101.79	3,951.85	35.29	--	66.17
Total Assets	2,980.53	8,073.64	91.69	--	92.39
Total Debt*	942.81	2,676.60	28.89	--	29.75
Net Current Assets	150.09	2,110.00	4.26	--	17.57
Contingent Liabilities	249.22	273.87	--	--	--

	Dishman Pharma & Chem	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	278.64	71.61	7.61	--	9.86
Cash Flow from Investing Activities	-152.89	-818.19	-7.87	--	-14.23
Cash from Financing Activities	-94.10	254.26	-0.26	--	4.37
Net Cash Inflow / Outflow	31.65	-492.32	-0.51	--	-0.01

	Dishman Pharma & Chem	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	14.40	6.87	7.44	--	35.54
ROE (%)	12.77	7.07	3.16	--	46.43
ROA (%)	5.91	3.25	1.04	--	13.87
EBIT Margin (%)	27.37	12.58	26.35	--	13.70
Net Margin (%)	10.54	5.57	2.31	--	8.08
Cash Profit Margin (%)	17.48	8.84	14.36	--	8.75

	Dishman Pharma & Chem	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	0.46	-0.63	-0.11	--	0.00
EBIT Growth (%)	9.32	-27.79	-10.14	--	24.42
Net Profit Growth (%)	42.79	-39.04	-65.67	--	0.00
EPS Growth (%)	42.82	-38.31	-65.67	--	0.00
Book Value Growth (%)	17.34	11.15	3.21	--	0.00

	Dishman Pharma & Chem	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	7.92	39.52	0.00	--	0.00
Price / Book Value	1.87	2.87	0.00	--	0.00
Dividend Yield (%)	0.60	0.00	--	--	--
EV/EBITDA	8.22	21.33	4.77	--	1.46
Market Cap (₹ Cr)	2,710.31	10,753.31	0.00	--	0.00

	Dishman Pharma & Chem	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.65	0.71	0.60	--	1.09
Short term debt to equity ratio	0.29	0.15	0.31	--	0.42
Current Ratio	1.16	2.15	1.14	--	1.36
Quick Ratio	0.65	1.55	1.07	--	0.96
Interest Coverage	3.47	3.24	2.12	--	7.92

	Dishman Pharma & Chem	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	9.54	24.96	48.35	--	23.62
Asset Turnover	0.55	0.58	0.45	--	1.68
Receivable days	42.08	75.93	166.45	--	86.20
Inventory Days	106.08	87.00	13.89	--	46.64
Payable days	129.38	134.61	247.85	--	113.37
Cash Conversion Cycle	18.78	28.32	-67.51	--	19.47

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.